Mycoplasma genitalium Treatment
For confirmed M. genitalium infection, treat with doxycycline 100 mg orally twice daily for 7 days followed by azithromycin 500 mg on day 1, then 250 mg daily for 4 days (extended azithromycin regimen), and obtain macrolide resistance testing whenever possible to guide subsequent therapy if treatment fails. 1, 2
Initial Treatment Approach
The two-step treatment strategy is now standard:
- Step 1: Doxycycline 100 mg orally twice daily for 7 days
- Step 2: Azithromycin 500 mg on day 1, then 250 mg daily for days 2-5
This sequential approach reduces bacterial load before macrolide exposure and decreases the risk of selecting for macrolide resistance 1, 3. The extended 5-day azithromycin regimen is superior to single-dose azithromycin 1g, which has treatment failure rates of 13.9% and drives resistance development in 12% of cases 3.
Macrolide Resistance-Guided Management
Macrolide resistance is now present in 55-56% of M. genitalium infections, making resistance testing critical 1, 4. However, FDA-approved resistance tests are not widely available in the United States 5.
When Macrolide Susceptibility is Confirmed:
- Doxycycline 100 mg twice daily for 7 days
- Followed by azithromycin 1g on day 1, then 500 mg daily for 3 days 6
When Macrolide Resistance is Confirmed or Testing Unavailable:
- First-line for resistance: Doxycycline 100 mg twice daily for 7 days, followed by moxifloxacin 400 mg once daily for 7 days (uncomplicated infection) or 14 days (complicated infection like PID or epididymitis) 1, 2
Critical caveat: Moxifloxacin carries FDA black box warnings for serious adverse effects including tendon rupture, peripheral neuropathy, and CNS effects. Fluoroquinolone resistance is also emerging, with rates of 20.6% reported in some regions 4.
Treatment Failure Management
When initial macrolide-guided therapy fails (occurring in 32.2% of cases) 7:
Third-Line Options:
Minocycline-based regimens:
- Minocycline 100 mg twice daily for 14 days alone (cure rate 40-70%) 1
- Minocycline 100 mg + metronidazole 400 mg, both twice daily for 14 days achieves 80.8% cure rate for macrolide-resistant infections, increasing to 90.3% when preceded by doxycycline 8
Pristinamycin:
- 1g four times daily for 10 days (cure rate ~75%) 1
- Availability is limited in the UK and United States 7
Pregnancy Considerations
In pregnancy, azithromycin is the only recommended first-line treatment 9. All guidelines agree:
- Use azithromycin (dosing varies between guidelines - either single 1g dose or extended regimen)
- Avoid moxifloxacin - contraindicated in pregnancy
- Pristinamycin safety data is inconsistent and should be avoided unless no alternatives exist 9
Testing is not recommended in asymptomatic pregnant patients without known M. genitalium exposure 5.
Follow-Up and Test of Cure
- Test of cure is mandatory 14-90 days after completing therapy 1, 2
- Use nucleic acid amplification testing (NAAT)
- Repeat resistance testing if treatment fails 6, 2
- Sexual abstinence until 7 days after completing therapy and symptoms resolve 10
- Partner notification and treatment is essential 10
Testing Indications (Avoid Overscreening)
Test only when indicated to prevent inappropriate antibiotic use 5, 1:
- Persistent or recurrent urethritis in men
- Cervicitis in women
- Pelvic inflammatory disease
- Proctitis
- Sexual contacts of confirmed M. genitalium cases
Do NOT test:
- Asymptomatic individuals without known exposure
- Asymptomatic pregnant women without exposure history 5
Key Pitfalls
- Avoid azithromycin 1g single dose - this drives resistance and has high failure rates 3
- Multiple moxifloxacin courses often fail - consider alternative regimens after first fluoroquinolone failure 7
- Resistance testing is underutilized - only 72.9% of samples are successfully tested despite availability 4
- Inappropriate screening occurs in 1 in 10 patients - adhere strictly to testing criteria 4
The landscape of M. genitalium treatment is rapidly evolving due to escalating antimicrobial resistance. The minocycline-metronidazole combination represents a promising globally accessible option for resistant infections where quinolones have failed or are contraindicated 8.